Modafinil: approved uses, evidence, legal status and risks

Key points

• Modafinil is a prescription wakefulness-promoting drug. The US label covers excessive sleepiness in narcolepsy, obstructive sleep apnea and shift work disorder; the EU and UK licences were narrowed to narcolepsy in 2011 [1][4][9].
• Its mechanism is officially “unknown”. It blocks the dopamine transporter, but the label does not say this explains the wakefulness effect [1][15].
• In healthy, rested adults, pooled cognitive effects are small: g = 0.10 in one meta-analysis, SMD 0.12 in another [17][18]. Under sleep deprivation it restored alertness for a few hours in small trials [19][21].
• Documented risks include serious skin reactions, psychiatric events, reduced effectiveness of hormonal contraceptives and unresolved questions in pregnancy [1][8][25][27].
• Long-term use in healthy people has not been well studied.

What is modafinil, and what is it approved for?

Modafinil, first sold as Provigil, is a regulated prescription medicine. It is not a peptide or a research chemical, so “research use only” labelling does not apply, and Peptilyze does not compare prices for prescription drugs.

The current US label says it is “indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD)”. In sleep apnea it treats the sleepiness, not the obstruction. It is not approved for any use in children [1]. FDA first approved Provigil on 24 December 1998 [2].

Europe narrowed the licence. After an Article 31 review, the EMA’s committee (CHMP) confirmed on 18 November 2010 that use “should be restricted to the treatment of narcolepsy”; the European Commission decided on 27 January 2011. Sleep apnea, shift work sleep disorder and idiopathic hypersomnia were removed because the benefit did not outweigh the risks. The EMA also advised against use in uncontrolled hypertension or irregular heartbeat and asked companies for cardiovascular and skin safety studies and for data on misuse by students [4]. Germany’s BfArM informed doctors on 11 February 2011 [5]; the UK regulator published its own notice [9]. The UK product text covers adults with narcolepsy and excludes under-18s [8].

Any other use, including cognitive enhancement in healthy people, is off-label.

How does modafinil work?

Not established. The label states that “the mechanism(s) through which modafinil promotes wakefulness is unknown” [1].

What is known: in vitro it binds the dopamine transporter (DAT) and inhibits dopamine reuptake, and in mice lacking DAT it had no wake-promoting effect. Yet in rats its effect was not blocked by a dopamine antagonist the way amphetamine’s was, and the label says it is “not a direct- or indirect-acting dopamine receptor agonist” [1]. A 2009 PET pilot in 10 healthy men found it occupied roughly 39-54% of dopamine transporters in the regions measured and raised extracellular dopamine, including in the nucleus accumbens [15]. A 2015 review lists indirect effects on serotonin, glutamate, orexin, histamine and GABA [16]; the label does not.

History: Lafon, Cephalon and the approvals

Billiard and Broughton (2018) trace modafinil to the French company L. Lafon, which identified adrafinil in 1974. Michel Jouvet gave adrafinil to narcolepsy patients from 1977-78, then its active metabolite modafinil from 1983. Lafon was at first not interested in developing it; the French army used it during the Gulf War in early 1991, and it was officially registered in France in 1992 [13]. Some websites give 1994; the cited review says 1992.

On 28 December 2001 Cephalon, which called Provigil its “flagship product”, announced it had completed the acquisition of Group Lafon and “now controls worldwide rights” to it [14]. More detail is planned in modafinil history; the R-enantiomer is covered in modafinil vs armodafinil.

Legal and prescription status

Country	Status	Source
US	Prescription drug; Schedule IV (21 CFR 1308.14, item 7)	[1][3]
UK	Prescription-only; not listed in Schedule 2 of the Misuse of Drugs Act 1971 or Schedules 1-5 of the 2001 Regulations (checked 8 Nov 2026)	[8][12]
Germany	Prescription-only (AMVV Anlage 1); not in Anlagen I-III of the BtMG (checked 8 Nov 2026)	[6][7]
Other EU states	Indications set by the 2011 Commission decision; scheduling is national and we could not verify each state against an official source	[4]

The US label says modafinil “produces psychoactive and euphoric effects” in humans, compared with methylphenidate in an abuse-potential study; one trial saw no withdrawal symptoms in 14 days after 9 weeks of use [1]. The MHRA has said modafinil is licensed for specific conditions, “not for use as a ‘boost’ during exams” [11]. A country-by-country overview is planned: modafinil legal status by country.

What does the evidence show in healthy, rested adults?

Review	What it pooled	Finding
Roberts 2020, meta-analysis [18]	14 studies, 64 effect sizes, acute dosing	Overall SMD 0.12 (p = .01); memory updating SMD 0.28 (p = .03); other subdomains not significant. Authors: effects “small”; user belief in efficacy “is not supported by the evidence so far”
Kredlow 2019, meta-analysis [17]	19 single-dose placebo-controlled trials, 67 effect sizes	g = 0.10 (95% CI 0.05-0.15); no difference between domains; no moderation by dose or psychiatric status; “limited potential” outside sleep deprivation
Battleday and Brem 2015, systematic review [16]	MEDLINE studies 1990 to Dec 2014	Simple tests: “only half” showed gains in attention and learning/memory, a few reported impaired divergent creative thinking. Complex tasks: more consistent gains. No excess side effects or mood change
Kelley 2012, military meta-analysis [20]	3 studies met criteria	“Relatively weak” pooled effect; main finding was a research gap

An older review found improved attention in well-rested people but concluded that “expectations regarding the effectiveness of these drugs exceed their actual effects” [19].

Two limits apply. Most trials gave one dose and measured performance for hours, so they say little about repeated or real-world use. And many used tests designed for patients, which may miss effects in healthy people [16]. See the planned healthy adults evidence review.

What does the evidence show under sleep deprivation?

Clearer, but small trials. In a 2005 trial, 48 healthy adults stayed awake 85 hours; after 64 hours, groups of 12 received placebo, caffeine, dextroamphetamine or modafinil. All three drugs improved psychomotor vigilance and objective alertness over placebo for about 2-4 hours; executive-task effects were mixed [21]. A 2009 trial of 54 healthy adults tested planning tasks after 45-50 hours awake: the modafinil group solved the Tower of London in fewer moves and made fewer perseverative errors on the Wisconsin Card Sorting Test, while caffeine did better on the Tower of Hanoi, so no drug won across tasks [22]. A 2010 review concluded that repeated doses did not prevent decline over longer sleep deprivation, and possibly induced “overconfidence” [19]. More in modafinil and sleep deprivation studies.

Risks and unknowns

Common adverse effects. In the label’s placebo-controlled trials in sleep-disorder patients, headache occurred in 34% on modafinil vs 23% on placebo, nausea 11% vs 3%, nervousness 7% vs 3%, anxiety 5% vs 1%, insomnia 5% vs 1%. Eight percent (74 of 934) stopped for an adverse reaction vs 3% on placebo [1]. A 2026 meta-analysis of 54 studies found patterns varying by condition, such as insomnia risk ratios of 5.82 in sleep apnea and 4.97 in ADHD [23]. These are patients, not healthy volunteers.

Serious skin and hypersensitivity reactions. The label warns of serious rash including Stevens-Johnson syndrome (SJS), and rare toxic epidermal necrolysis (TEN) and DRESS, in adults and children. In pediatric trials, rash led to discontinuation in about 0.8% (13 of 1,585), including one possible SJS case, against none among 380 children on placebo. The label says the reporting rate of TEN and SJS “exceeds the background incidence rate” of 1-2 cases per million person-years, even though reports are undercounted. Nearly all serious rashes appeared within 1-5 weeks, isolated cases later, and no factor predicts which rashes turn serious. Multi-organ hypersensitivity, with at least one fatality, has also been reported [1]. The UK text says treatment should stop at the first sign of rash [8].

Psychiatric and cardiovascular effects. Postmarketing reports include mania, delusions, hallucinations, suicidal ideation and aggression, some requiring hospitalisation [1]. A 2026 systematic review of 24 case reports found hallucinations in 66.7% and delusions in 58.3%, sometimes at therapeutic doses; it cannot give an incidence [24]. The label does not recommend use with left ventricular hypertrophy or prior mitral valve prolapse syndrome on stimulants [1]; the EMA advised against it in uncontrolled hypertension and arrhythmia [4].

Interactions, including hormonal contraceptives. Modafinil can induce CYP3A4/5. The FDA label says the effectiveness of steroidal contraceptives “may be reduced” and recommends alternative or additional contraception during treatment and for one month after; the UK text says two months [1][8], as did the MHRA in 2020 [10]. The label also reports lower cyclosporine levels, prolonged elimination of CYP2C19 substrates (phenytoin, diazepam, propranolol, omeprazole), closer INR monitoring with warfarin, and caution with MAO inhibitors [1]. See side effects and interactions.

Pregnancy. The US label (still using the older “Category C” wording) says there are no adequate studies in pregnant women, notes reports of intrauterine growth restriction and spontaneous abortion, and reports developmental toxicity in rats and rabbits [1]. The UK text says it “should not be used during pregnancy” [8]. Human data conflict:

• Danish registers: 49 exposed pregnancies, 6 major malformations (12%) vs 3.9% unexposed; adjusted OR 2.7 (95% CI 1.1-6.9) [25].
• Sweden and Norway: 133 exposed among 1,917,605 pregnancies; 3 infants (2.3%, 3 of 133) with major malformations vs 2.1% unexposed; the paper’s crude relative risk was 1.06 with a wide confidence interval (0.35-3.25), so the study could not rule out a difference in either direction [26].
• US manufacturer registry, 14 years, 191 pregnancies: 13.1% (18 of 137) of prospective live births vs a 3% population rate; the authors work for or consult for the manufacturer [27].
• European teratology services, 175 prospective cases: 2.0% non-chromosomal major anomalies among 150 live births, with a tendency to lower birth weight and smaller head circumference [28].

Not well studied: long-term use in healthy adults; repeated use outside sleep deprivation; children (a 6-week trial of 165 children with narcolepsy found no significant benefit over placebo [1]); real-world cognitive tasks; and the mechanism itself.

How modafinil appears in the source tier lists

Three social posts in our source set bear on it. They are individuals’ opinions, and none cites a study.

• @dex7official (20 October 2026) ranks modafinil D on a cognitive-enhancement list, alongside armodafinil, Semax, Selank, L-theanine and alpha-GPC; coffee is a tier higher, in C [29]. Verdict: partly supported. A low placement fits the small pooled effects [17][18], and caffeine matched modafinil on alertness for 2-4 hours in a sleep-deprivation trial [21]. But the list states no criteria, so the rank cannot be tested.
• @theriac33 (2 November 2026) puts modafinil under “what your dopamine loves” [29]. Verdict: partly supported. The PET pilot of 10 men found raised extracellular dopamine [15], but the label says the wakefulness mechanism is unknown [1], and “loves” is not a measured outcome. The graphic also contains an error our transcription flagged (a flavone labelled “Prolactin”).
• @Hoostethics lists modafinil in neither transcribed list (looksmaxxing, 22 October; “cope supplements”, 15 October) [29]. Absence is not a judgement.

The lists disagree, and rankings by individuals are not evidence. See why rankings disagree.

Frequently asked questions

Is modafinil approved for cognitive enhancement?

No. FDA approval covers excessive sleepiness in narcolepsy, sleep apnea and shift work disorder; EU and UK approval covers narcolepsy only [1][4][8]. Use for cognition in healthy people is off-label.

How large are the effects in healthy adults?

Small. Two meta-analyses reported g = 0.10 (19 trials) and SMD 0.12 (14 studies), mostly single-dose lab experiments [17][18]. One review found impaired creative thinking on divergent tasks in a few studies [16].

Does modafinil affect birth control?

The FDA label says it may reduce the effectiveness of steroidal contraceptives through enzyme induction, for one month after stopping; the UK text says two months [1][8].

Is modafinil a controlled substance?

In the US it is Schedule IV [3]. It is not scheduled under UK Misuse of Drugs legislation or the German BtMG, but is prescription-only in both [6][7][8][12].

Sources

1. Apotex Corp., “PROVIGIL (modafinil) tablets, prescribing information”, DailyMed (revised February 2025). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0391f182-1958-9fef-a944-53b229ce99e7
2. FDA, “Drugs@FDA: NDA 020717 Provigil, overview” (accessed 2026-11-08). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020717
3. US Government, “21 CFR 1308.14 Schedule IV” (Cornell LII reproduction of the eCFR; accessed 2026-11-08). https://www.law.cornell.edu/cfr/text/21/1308.14
4. EMA, “Modafinil - referral” (EMEA/H/A-31/1186; CHMP opinion 18 Nov 2010, Commission decision 27 Jan 2011). https://www.ema.europa.eu/en/medicines/human/referrals/modafinil
5. BfArM, “Rote-Hand-Brief zu Vigil (Modafinil): eingeschränkte Indikation” (11 Feb 2011). https://bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RHB/2011/rhb-vigil.pdf
6. Bundesministerium der Justiz, “Betäubungsmittelgesetz, Anlagen I-III” (accessed 2026-11-08). https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html
7. Bundesministerium der Justiz, “AMVV Anlage 1” (accessed 2026-11-08). https://www.gesetze-im-internet.de/amvv/anlage_1.html
8. Milpharm Ltd, “Modafinil 200 mg tablets, SmPC”, electronic medicines compendium (revised 14 Feb 2024). https://www.medicines.org.uk/emc/product/4320/smpc
9. MHRA, “Modafinil (Provigil): now restricted to narcolepsy”, Drug Safety Update (originally March 2011). https://www.gov.uk/drug-safety-update/modafinil-provigil-now-restricted-to-narcolepsy
10. MHRA, “Sleep disorder drug modafinil linked to increased risk of birth defects and also to reduced effectiveness of contraception” (16 Nov 2020). https://www.gov.uk/government/news/sleep-disorder-drug-modafinil-linked-to-increased-risk-of-birth-defects-and-also-to-reduced-effectiveness-of-contraception
11. MHRA, “Freshers warned to be smart and avoid Modafinil” (26 Sep 2016). https://www.gov.uk/government/news/freshers-warned-to-be-smart-and-avoid-modafinil
12. legislation.gov.uk, “Misuse of Drugs Act 1971, Schedule 2” and “Misuse of Drugs Regulations 2001, Schedules 1-5” (accessed 2026-11-08). https://www.legislation.gov.uk/uksi/2001/3998/schedule/4
13. Billiard M, Broughton R, “Modafinil: its discovery, the early European and North American experience…”, Sleep Med 2018;49:69-72. https://pubmed.ncbi.nlm.nih.gov/30174215/
14. Cephalon, press release on completion of the Group Lafon acquisition, SEC Form 8-K exhibit 99.1 (28 Dec 2001). https://www.sec.gov/Archives/edgar/data/0000873364/000091205702000878/a2067212zex-99_1.txt
15. Volkow ND et al., “Effects of modafinil on dopamine and dopamine transporters in the male human brain”, JAMA 2009;301:1148-54. https://pubmed.ncbi.nlm.nih.gov/19293415/
16. Battleday RM, Brem AK, “Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review”, Eur Neuropsychopharmacol 2015;25:1865-81. https://pubmed.ncbi.nlm.nih.gov/26381811/
17. Kredlow MA et al., “The efficacy of modafinil as a cognitive enhancer: a systematic review and meta-analysis”, J Clin Psychopharmacol 2019;39:455-61. https://pubmed.ncbi.nlm.nih.gov/31433334/
18. Roberts CA et al., “How effective are pharmaceuticals for cognitive enhancement in healthy adults?”, Eur Neuropsychopharmacol 2020;38:40-62. https://pubmed.ncbi.nlm.nih.gov/32709551/
19. Repantis D et al., “Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review”, Pharmacol Res 2010;62:187-206. https://pubmed.ncbi.nlm.nih.gov/20416377/
20. Kelley AM et al., “Cognition enhancement by modafinil: a meta-analysis”, Aviat Space Environ Med 2012;83:685-90. https://pubmed.ncbi.nlm.nih.gov/22779312/
21. Wesensten NJ et al., “Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation”, J Sleep Res 2005;14:255-66. https://pubmed.ncbi.nlm.nih.gov/16120100/
22. Killgore WD et al., “Sustaining executive functions during sleep deprivation”, Sleep 2009;32:205-16. https://pubmed.ncbi.nlm.nih.gov/19238808/
23. Jung J et al., “Assessing condition-specific adverse event profiles of modafinil…”, Basic Clin Pharmacol Toxicol 2026;138:e70147. https://pubmed.ncbi.nlm.nih.gov/41367108/
24. Sato Y et al., “Modafinil-associated psychosis: a systematic review”, Ther Adv Psychopharmacol 2026;16. https://pubmed.ncbi.nlm.nih.gov/42137740/
25. Damkier P, Broe A, “First-trimester pregnancy exposure to modafinil and risk of congenital malformations”, JAMA 2020;323:374-6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6990936/
26. Cesta CE et al., “Incidence of malformations after early pregnancy exposure to modafinil in Sweden and Norway”, JAMA 2020;324:895-7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7489822/
27. Kaplan S et al., “Pregnancy and fetal outcomes following prenatal exposure to modafinil and/or armodafinil: a 14-year registry study”, Neurol Clin Pract 2025;15:e200551. https://pubmed.ncbi.nlm.nih.gov/41070135/
28. Onken M et al., “Effects of maternal modafinil treatment on fetal development and neonatal growth parameters (ENTIS)”, Acta Psychiatr Scand 2024;150:372-84. https://pubmed.ncbi.nlm.nih.gov/38110225/
29. X posts read through the fxtwitter mirror, with tier placements read from the images on 2026-11-08: @dex7official (2026-10-20) https://x.com/dex7official/status/2112691493261484516 ; @theriac33 (2026-11-02) https://x.com/theriac33/status/2117361887457505469 ; @Hoostethics (2026-10-15) https://x.com/Hoostethics/status/2110728908735979632 . Claims, not evidence.

This article is information, not medical advice.